Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017522 · ClinicalTrials.gov registry record · NA
Non-Invasive Characterization in Cardiac Sarcoidosis
A NA study, sponsored by University of Michigan.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02017522: Clinical Trial NA study, sponsored by University of Michigan.
NCT02017522 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02017522, a NA study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
In a study of Cardiac sarcoidosis, a serious heart condition, a radiotracer is being used to examine inflammation.
Primary Outcome
The primary outcome of this study will be the ratio of 11C-PBR28 PET activity in myocardial regions with inflammation indicated by FDG PET and/or edema indicated by increased T2 signal with cardiac MRI compared to the 11C-PBR28 PET activity in myocardial segments which appear normal on FDG PET and cardiac MRI. The primary outcome is thus the intensity of uptake in abnormal regions as a percentage of the intensity of uptake in normal segments.
Interventions
- DEVICE 11C-PBR PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-04-04 |
| Est. Completion | 2015-07-07 |
| Phase | NA |
Why NCT02017522 stopped before completion
NCT02017522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which 11C-PBR PET is the first listed.
NCT02017522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02017522 about?
NCT02017522 is a clinical study titled "Non-Invasive Characterization in Cardiac Sarcoidosis". In a study of Cardiac sarcoidosis, a serious heart condition, a radiotracer is being used to examine inflammation.
What is the current status of trial NCT02017522?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2014-04-04. Estimated completion is 2015-07-07.
What interventions are being tested in trial NCT02017522?
The interventions under investigation include: 11C-PBR PET (DEVICE).
Who is sponsoring clinical trial NCT02017522?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02017522's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI